This article was published in Scientific American’s former blog network and reflects the views of the author, not necessarily those of Scientific American
On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
The article "Race in a Bottle" by Jonathan Kahn supplies a critical analysis of the approval of the first ethnic drug, a heart failure medication for African-Americans. It provoked an immediate reaction from NitroMed, the drug's maker, and from the Association of Black Cardiologists, both of which defended the designation of self-identified race as an imperfect but still useful means of ascertaining genetic variation within a population and, by consequence, differences in drug response that warranted FDA approval. "Race in a Bottle" is free to readers. And we have included a package of responses and related links as part of our InFocus features section. Readers can access responses from NitroMed, the Association of Black Cardiologists and a reply from the author. We are very interested in reader opinions on this highly controversial subject.